药物洗脱支架在预防支架内再狭窄中的作用及临床应用进展

Effects and clinical advances of drug-eluting stent in preventing in-stent restenosis

冠状动脉支架植入术已成为冠心病治疗中一种有确切疗效的重要手段 ,但相当高 (10 %～ 5 0 %)的支架内再狭窄率限制了支架植入术的发展。而可在局部缓慢释放抑制血管内皮和平滑肌增殖药物的药物洗脱支架 (DES)的应用 ,明显降低了支架内再狭窄率 ,大大延缓了支架术后再次行经皮冠状动脉介入治疗的时间。目前临床应用的DES有雷帕霉素洗脱支架和紫杉醇洗脱支架 ,其显著降低支架内再狭窄率的作用已为越来越多的已完成或正在进行的临床试验所证实。

Percutaneous coronary stenting has become a major method in coronary heart disease treatment with exact efficacy . But higher in-stent restenosis rate (about 10%-50%) hampered its development. Recent usage of drug-eluting stent(DES) dramatically decreased the in-stent restenosis rate and postponed additional percutanenous coronary intervention(PCI) by giving off antiproliferative agents slowly on smooth muscle cells and endothelial cells. CypherTM stent and TaxusTM stent were the only DESs in clinical use now days, and their positive effects have been proved by more and more clinical trials.